EE9800315A - Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil - Google Patents

Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil

Info

Publication number
EE9800315A
EE9800315A EE9800315A EE9800315A EE9800315A EE 9800315 A EE9800315 A EE 9800315A EE 9800315 A EE9800315 A EE 9800315A EE 9800315 A EE9800315 A EE 9800315A EE 9800315 A EE9800315 A EE 9800315A
Authority
EE
Estonia
Prior art keywords
heart failure
treating heart
endothelin antagonists
blooded animal
warm blooded
Prior art date
Application number
EE9800315A
Other languages
English (en)
Estonian (et)
Inventor
J. Lynch Joseph Jr.
Shen You-Tang
Original Assignee
Banyu Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharmaceutical Co., Ltd. filed Critical Banyu Pharmaceutical Co., Ltd.
Publication of EE9800315A publication Critical patent/EE9800315A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
EE9800315A 1996-04-04 1997-03-19 Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil EE9800315A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1488296P 1996-04-04 1996-04-04
PCT/US1997/003737 WO1997037665A1 (en) 1996-04-04 1997-03-19 Method of treating heart failure with endothelin antagonists

Publications (1)

Publication Number Publication Date
EE9800315A true EE9800315A (et) 1999-06-15

Family

ID=21768326

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800315A EE9800315A (et) 1996-04-04 1997-03-19 Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil

Country Status (25)

Country Link
US (3) US5834483A (xx)
EP (1) EP0906108B1 (xx)
JP (2) JP3345891B2 (xx)
KR (1) KR20000005178A (xx)
CN (1) CN1215335A (xx)
AT (1) ATE297739T1 (xx)
AU (1) AU723351B2 (xx)
BG (1) BG102716A (xx)
BR (1) BR9708525A (xx)
CA (1) CA2249330C (xx)
CZ (1) CZ296098A3 (xx)
DE (1) DE69733557T2 (xx)
EA (1) EA003587B1 (xx)
EE (1) EE9800315A (xx)
ES (1) ES2241047T3 (xx)
HU (1) HUP9903893A3 (xx)
IL (1) IL126175A (xx)
IS (1) IS4847A (xx)
NO (1) NO984564L (xx)
NZ (1) NZ331789A (xx)
PL (1) PL329077A1 (xx)
SK (1) SK130098A3 (xx)
TR (1) TR199801988T2 (xx)
UA (1) UA50761C2 (xx)
WO (1) WO1997037665A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA50761C2 (uk) 1996-04-04 2002-11-15 Банью Фармасьютікал Ко., Лтд. Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
WO1998006700A1 (en) * 1996-08-09 1998-02-19 Merck & Co., Inc. Stereoselective deoxygenation reaction
WO1999037639A1 (en) 1998-01-21 1999-07-29 Banyu Pharmaceutical Co., Ltd. Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1577310A1 (en) * 2002-12-27 2005-09-21 Kaneka Corporation Processes for producing optically active 2-thiomethyl-3-phenylpropionic acid derivative and for producing intermediate therefor
MXPA06005518A (es) 2003-11-17 2006-08-17 Novartis Ag Uso de inhibidores de la dipeptidil peptidasa iv.
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
TW200605867A (en) 2004-03-17 2006-02-16 Novartis Ag Use of organic compounds
JP4967136B2 (ja) 2005-06-24 2012-07-04 国立大学法人 東京医科歯科大学 薬剤溶出性ステント
TW201136582A (en) 2010-03-16 2011-11-01 Novartis Ag Improved pharmaceutical compositions of aliskiren and methods of delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
CN1049219C (zh) * 1993-08-18 2000-02-09 万有制药株式会社 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
UA50761C2 (uk) * 1996-04-04 2002-11-15 Банью Фармасьютікал Ко., Лтд. Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини

Also Published As

Publication number Publication date
PL329077A1 (en) 1999-03-15
CN1215335A (zh) 1999-04-28
NO984564L (no) 1998-12-04
EA003587B1 (ru) 2003-06-26
BG102716A (en) 1999-09-30
EP0906108A4 (en) 2000-12-06
AU2202597A (en) 1997-10-29
ES2241047T3 (es) 2005-10-16
JP2000510824A (ja) 2000-08-22
CA2249330C (en) 2005-08-09
AU723351B2 (en) 2000-08-24
NO984564D0 (no) 1998-09-30
UA50761C2 (uk) 2002-11-15
JP2002220337A (ja) 2002-08-09
CZ296098A3 (cs) 1999-06-16
JP3345891B2 (ja) 2002-11-18
US6087360A (en) 2000-07-11
HUP9903893A3 (en) 2001-05-28
IS4847A (is) 1998-09-15
WO1997037665A1 (en) 1997-10-16
EP0906108B1 (en) 2005-06-15
HUP9903893A2 (hu) 2001-04-28
CA2249330A1 (en) 1997-10-16
ATE297739T1 (de) 2005-07-15
KR20000005178A (ko) 2000-01-25
TR199801988T2 (xx) 2000-08-21
US6380195B1 (en) 2002-04-30
NZ331789A (en) 2000-05-26
DE69733557D1 (de) 2005-07-21
BR9708525A (pt) 1999-08-03
IL126175A (en) 2003-05-29
EP0906108A1 (en) 1999-04-07
SK130098A3 (en) 1999-05-07
IL126175A0 (en) 1999-05-09
DE69733557T2 (de) 2005-11-03
US5834483A (en) 1998-11-10
EA199800889A1 (ru) 1999-04-29

Similar Documents

Publication Publication Date Title
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
CY1106046T1 (el) Μεθοδος για την θεραπευτικη αγωγη ινωσεως με χρησιμοποιηση ενος ανταγωνιστου της αλφα-4-υπομοναδος της ιντεγκρινης
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
HK1044333A1 (zh) 趨化因子受體拮抗劑及其使用方法
IL130083A0 (en) 3-Pyridyl enantiomers and their use as analgesics
DE60101339D1 (de) Stimulierung des knochenwachstums mit peptidderivaten von thrombin
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
DE69637050D1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
ATE226436T1 (de) Neue verwendung von dexmedetomidin
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
NO20003313L (no) Terapeutiske midler
EA200100716A1 (ru) Способ профилактики рака молочной железы
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
DK1058544T3 (da) Inhibition af TNF-aktivitet med præparater, der omfatter heparin og oplöselige TNF-receptorer
AR008155A1 (es) Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
HK1015708A1 (en) Use of muteins of wild-type cytokines as immunogens.
DK0572549T3 (da) Behandling af ikke-småcellet lungecarcinom
EA200100041A1 (ru) Способ лечения